Iovance Biotherapeutics, Inc.
IOVANasdaqCIK 1425205HealthcareFiscal year ends Dec 31
Reports and events: 372 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2917:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-120261 |
| 2026-10-0517:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-113763 |
| 2026-09-2907:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-111583 |
| 2026-08-0617:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-092145 |
| 2026-08-0609:15 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-091716 |
| 2026-08-0607:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091619 |
| 2026-07-0217:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080409 |
| 2026-06-1017:01 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-072408 |
| 2026-05-0709:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-056782 |
| 2026-05-0709:16 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-056778 |
| 2026-04-2817:01 ET | DEF 14A | Proxy statementPeriod 2026-06-10 | 0001104659-26-050458 |
| 2026-03-2017:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-26-032774 |
| 2026-02-2409:35 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-018899 |
| 2026-02-2408:00 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-018837 |
| 2026-01-0907:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-002323 |
| 2025-11-0609:15 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-107470 |
| 2025-11-0608:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-107426 |
| 2025-08-2916:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-085650 |
| 2025-08-2217:18 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-25-081953 |
| 2025-08-1916:47 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-080304 |
| 2025-08-0717:16 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-010807 |
| 2025-08-0716:06 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-25-075175 |
| 2025-07-1507:36 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-067940 |
| 2025-07-0316:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-25-065781 |
| 2025-06-1317:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-25-059464 |
| 2025-06-1017:15 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-058199 |
| 2025-05-0817:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-007009 |
| 2025-05-0816:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-046101 |
| 2025-04-2817:00 ET | DEF 14A | Proxy statementPeriod 2025-06-10 | 0001558370-25-005702 |
| 2025-02-2717:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-001834 |
| 2025-02-2716:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-018212 |
| 2025-02-1007:22 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-010729 |
| 2024-11-2117:15 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001104659-24-121612 |
| 2024-11-0821:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-115444 |
| 2024-11-0717:15 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-014905 |
| 2024-11-0716:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-115300 |
| 2024-08-0917:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-087876 |
| 2024-08-0817:10 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-011641 |
| 2024-08-0816:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-087259 |
| 2024-06-2807:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-075997 |
| 2024-06-1117:15 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-070470 |
| 2024-06-0308:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-067485 |
| 2024-05-2420:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-064825 |
| 2024-05-0917:10 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001558370-24-007646 |
| 2024-05-0916:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-059322 |
| 2024-04-2917:06 ET | DEF 14A | Proxy statementPeriod 2024-06-11 | 0001558370-24-006148 |
| 2024-04-0317:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-043158 |
| 2024-03-2917:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-24-041200 |
| 2024-03-1917:19 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-036221 |
| 2024-03-0408:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-030249 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 17:02 ET. Listed shows no prices and gives no investment advice.